266 related articles for article (PubMed ID: 15745077)
1. Occurrence of gastrointestinal opportunistic disorders in AIDS despite the use of highly active antiretroviral therapy.
Mönkemüller KE; Lazenby AJ; Lee DH; Loudon R; Wilcox CM
Dig Dis Sci; 2005 Feb; 50(2):230-4. PubMed ID: 15745077
[TBL] [Abstract][Full Text] [Related]
2. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy.
Mönkemüller KE; Call SA; Lazenby AJ; Wilcox CM
Am J Gastroenterol; 2000 Feb; 95(2):457-62. PubMed ID: 10685750
[TBL] [Abstract][Full Text] [Related]
3. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.
Losina E; Yazdanpanah Y; Deuffic-Burban S; Wang B; Wolf LL; Messou E; Gabillard D; Seyler C; Freedberg KA; Anglaret X
Antivir Ther; 2007; 12(4):543-51. PubMed ID: 17668563
[TBL] [Abstract][Full Text] [Related]
4. Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.
Gerna G; Piccinini G; Genini E; Percivalle E; Zavattoni M; Lilleri D; Testa L; Comolli G; Maserati R; Baldanti F; Maccario R; Monforte AD; Revello MG
J Acquir Immune Defic Syndr; 2001 Dec; 28(4):320-31. PubMed ID: 11707667
[TBL] [Abstract][Full Text] [Related]
5. Upper gastrointestinal endoscopic findings in the era of highly active antiretroviral therapy.
Nkuize M; De Wit S; Muls V; Arvanitakis M; Buset M
HIV Med; 2010 Jul; 11(6):412-7. PubMed ID: 20146733
[TBL] [Abstract][Full Text] [Related]
6. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.
Murphy EL; Collier AC; Kalish LA; Assmann SF; Para MF; Flanigan TP; Kumar PN; Mintz L; Wallach FR; Nemo GJ;
Ann Intern Med; 2001 Jul; 135(1):17-26. PubMed ID: 11434728
[TBL] [Abstract][Full Text] [Related]
7. Predictive clinical factors in the diagnosis of gastrointestinal Kaposi's sarcoma and its endoscopic severity.
Nagata N; Shimbo T; Yazaki H; Asayama N; Akiyama J; Teruya K; Igari T; Ohmagari N; Oka S; Uemura N
PLoS One; 2012; 7(11):e46967. PubMed ID: 23226197
[TBL] [Abstract][Full Text] [Related]
8. [Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy].
Reus S; Portilla J; Gimeno A; Sánchez-Payá J; García-Henarejos JA; Martínez-Madrid O; Usó J; Roca B; Galindo MJ; López-Aldeguer J
Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):142-9. PubMed ID: 14987534
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for Kaposi's sarcoma in human immunodeficiency virus patients after initiation of antiretroviral therapy: A nested case-control study in Kenya.
Lupia R; Wabuyia PB; Otiato P; Fang CT; Tsai FJ
J Microbiol Immunol Infect; 2017 Dec; 50(6):781-788. PubMed ID: 26712092
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of T-cell subsets and their relationship with oral and systemic opportunistic infections in HIV/AIDS patients during the first year of HAART in Guangxi, China.
Zhang L; Huang Y; Liu Z; Liu W; Qin Q; Tao R
J Med Virol; 2015 Jul; 87(7):1158-67. PubMed ID: 25777553
[TBL] [Abstract][Full Text] [Related]
11. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
[TBL] [Abstract][Full Text] [Related]
12. [Study on the effect of treatment and the status of drug resistance among HIV/AIDS patients treated with highly active antiretroviral therapy in Shandong province].
Zhang J; Lin B; Lin L; Yang PJ; Fu JH; Li HP; Li JY
Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Nov; 28(11):1108-11. PubMed ID: 18396667
[TBL] [Abstract][Full Text] [Related]
13. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
Gandhi T; Wei W; Amin K; Kazanjian P
Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and determinants of glucose intolerance among HIV/AIDS patients in north-central Nigeria.
Reng SR; Uloko EA; Puepet HF; Onwuegbuzie AG; Ramalan AM
Niger J Med; 2016; 25(2):128-32. PubMed ID: 29944309
[TBL] [Abstract][Full Text] [Related]
15. [Effect of triple antiretroviral therapy on Tunisian AIDS profile: study of 139 cases].
Zouiten F; Ammari L; Goubantini A; Tiouiri H; Slim A; Maamouri A; Kilani B; Kanoun F; Marrakchi C; Neifer N; Mihoub L; Jenhani F; Garbouj M; Ben Chaabane T
Tunis Med; 2003 Dec; 81(12):956-62. PubMed ID: 14986532
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
[TBL] [Abstract][Full Text] [Related]
18. T-cell response of advanced aids patients after highly active antiretroviral therapy.
Wang AX; Li TS; Cao YZ; Han Y; Qiu ZF; Xie J
Chin Med Sci J; 2005 Dec; 20(4):223-5. PubMed ID: 16422247
[TBL] [Abstract][Full Text] [Related]
19. Association between Highly Active Antiretroviral Therapy and Type of Infectious Respiratory Disease and All-Cause In-Hospital Mortality in Patients with HIV/AIDS: A Case Series.
Báez-Saldaña R; Villafuerte-García A; Cruz-Hervert P; Delgado-Sánchez G; Ferreyra-Reyes L; Ferreira-Guerrero E; Mongua-Rodríguez N; Montero-Campos R; Melchor-Romero A; García-García L
PLoS One; 2015; 10(9):e0138115. PubMed ID: 26379281
[TBL] [Abstract][Full Text] [Related]
20. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
